MedImmune LLC
- Country
- ๐บ๐ธUnited States
- Ownership
- Subsidiary
- Established
- 1987-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://medimmune.com
A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Continuous Intravenous Infusion of MEDI-538 in Adults With B-Cell Chronic Lymphocytic Leukemia (CLL)
- First Posted Date
- 2008-05-13
- Last Posted Date
- 2008-09-05
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 30
- Registration Number
- NCT00676871
A Study to Evaluate the Safety, Tolerability and Effects of MEDI-563 in Adults With Asthma
- First Posted Date
- 2008-04-16
- Last Posted Date
- 2012-10-10
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 27
- Registration Number
- NCT00659659
- Locations
- ๐จ๐ฆ
Research Site, Quebec, Canada
CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
- Conditions
- Acute Lymphoblastic LeukemiaNon-Hodgkin's Lymphoma
- Interventions
- Drug: CAT-8015 (Moxetumomab Pasudotox)
- First Posted Date
- 2008-04-16
- Last Posted Date
- 2017-10-02
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 57
- Registration Number
- NCT00659425
- Locations
- ๐จ๐ฆ
Research Site, Toronto, Ontario, Canada
A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus
- Conditions
- LupusLupus Erythematosus, Systemic
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2016-08-09
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 87
- Registration Number
- NCT00657189
- Locations
- ๐บ๐ธ
Research Site, Seattle, Washington, United States
A Study to Describe Pediatric Influenza Vaccine Coverage
- Conditions
- Healthy
- Interventions
- Biological: Influenza vaccination
- First Posted Date
- 2008-03-20
- Last Posted Date
- 2014-09-15
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 147494
- Registration Number
- NCT00639418
- Locations
- ๐บ๐ธ
Lynne Ellis, St. Petersburg, Florida, United States
๐บ๐ธAssociates in Pediatrics, Baton Rouge, Louisiana, United States
๐บ๐ธPediatric and Adolescent Healthcare, PC, Marietta, Georgia, United States
A Study to Assess the Efficacy, Safety, and Tolerability of CAT-354 in Subjects With Asthma
- Conditions
- Asthma
- Interventions
- Other: PlaceboBiological: CAT-354 5 mg/kgBiological: CAT-354 1 mg/kgOther: CAT-354 10 mg/kg
- First Posted Date
- 2008-03-20
- Last Posted Date
- 2017-01-31
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 14
- Registration Number
- NCT00640016
- Locations
- ๐ฌ๐ง
Belfast City Hospital, Belfast, United Kingdom
๐ฆ๐บLung Institute WA, Sir Charles Gardner Hospital, Nedlands, Western Australia, Australia
๐ฆ๐บWA Lung Research, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
A Study to Assess Bioavailability and Pharmacokinetics of CAT- 354
- Conditions
- AsthmaHealthy
- Interventions
- Biological: CAT-354 150 mg (subcutaneous)Biological: CAT-354 150 mg (intravenous)Biological: CAT-354 300 mg (subcutaneous)
- First Posted Date
- 2008-03-19
- Last Posted Date
- 2017-05-04
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 30
- Registration Number
- NCT00638989
- Locations
- ๐บ๐ธ
MDS Pharma Services (US) Inc., Lincoln, Nebraska, United States
A Phase 3 Trial of the Effect of Motavizumab Prophylaxis on Reduction of Serious Early Childhood Wheezing in Infants
- Conditions
- Wheezing
- Interventions
- Biological: MotavizumabOther: Placebo
- First Posted Date
- 2008-03-05
- Last Posted Date
- 2012-08-01
- Lead Sponsor
- MedImmune LLC
- Registration Number
- NCT00628303
A Study to Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast Cancer
- First Posted Date
- 2008-03-03
- Last Posted Date
- 2010-02-03
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 56
- Registration Number
- NCT00627627
- Locations
- ๐บ๐ธ
Lynn Regional Cancer - West Campus, Boca Raton, Florida, United States
๐บ๐ธ"Duke University Med Cntr Breast Oncology Research Program, Durham, North Carolina, United States
๐บ๐ธCleveland Clinic Medical Center, Cleveland, Ohio, United States
A Post Marketing Evaluation of the Effectiveness of FluMist Risk Minimization Plan in Children
- First Posted Date
- 2008-02-29
- Last Posted Date
- 2014-08-12
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 321697
- Registration Number
- NCT00626808
- Locations
- ๐บ๐ธ
Research Site, Research Triangle, North Carolina, United States